The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Time to response and OS in patients with IDH1-mutated AML treated with olutasidenib
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, comments on the use of olutasidenib in patients with relapsed/refractory (R/R) IDH1-mutated acute myeloid leukemia (AML), highlighting that while the drug is well-tolerated, patients may take up to 10 months to achieve an optimal response. Dr Wang encourages community providers to give the drug more time, potentially up to six months, to allow for a full response. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
